Zinger Key Points
- Cassava Sciences' upcoming conference call on August 8 and plans to extend simufilam trials.
- The passing of long-time board member Sanford "Sandy" Robertson and his contributions to the company.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
Cassava Sciences, Inc. SAVA shares are trading higher Monday. Here’s what you need to know.
What To Know: Cassava Sciences is scheduled to hold a conference call on Thursday, August 8 2024, to discuss recent developments and provide a company update. Analysts expect the company to report an earnings per share (EPS) loss of 40 cents.
Additionally last week, Cassava announced plans to extend its open-label extension trials for simufilam by up to 36 months, allowing patients from previous trials to continue their treatment while awaiting Phase 3 trial results.
In Memoriam: Cassava Sciences also mourns the loss of long-time board member Sanford “Sandy” Robertson, who served on the Board of Directors since the company’s inception as a public entity in 1998.
SAVA Price Action: Cassava Sciences shares were up by 20.9% at $35.20, according to Benzinga Pro.
See Also:
Photo by solarseven on Shutterstock.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
